"Depsipeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized.
| Descriptor ID |
D047630
|
| MeSH Number(s) |
D04.345.566.297 D12.644.641.297
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Depsipeptides".
Below are MeSH descriptors whose meaning is more specific than "Depsipeptides".
This graph shows the total number of publications written about "Depsipeptides" by people in this website by year, and whether "Depsipeptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 0 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Depsipeptides" by people in Profiles.
-
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy. Ann Oncol. 2021 10; 32(10):1295-1297.
-
[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2]. Rev Esp Quimioter. 2021 Oct; 34(5):402-407.
-
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. Antimicrob Agents Chemother. 2021 03 18; 65(4).
-
SARS-CoV-2 dependence on host pathways. Science. 2021 02 26; 371(6532):884-885.
-
New Hopes for Drugs against COVID-19 Come from the Sea. Mar Drugs. 2021 Feb 11; 19(2).
-
Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors. Molecules. 2021 Feb 10; 26(4).
-
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021 02 26; 371(6532):926-931.
-
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. Ann Hematol. 2019 Sep; 98(9):2139-2150.
-
Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol. 2018 11 01; 201(9):2744-2752.
-
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. AIDS. 2018 08 24; 32(13):1793-1802.